Systemic scleroderma involves more widespread areas of tissue change but may begin as patches of hardened or tightened skin, especially in cutaneous systemic sclerosis, a subtype of systemic ...

Genes may play a role. Denton, CP and Black CM. “Scleroderma (systemic sclerosis).” In: Wolff K, Goldsmith LA, et al. Fitzpatrick’s Dermatology in General Medicine (seventh edition). McGraw Hill ...

When scleroderma affects an internal organ, the person has a type of scleroderma called systemic sclerosis. There are 2 types of systemic sclerosis: Limited cutaneous scleroderma: This often develops ...

Acute and chronic renal diseases remain common complications of systemic sclerosis. Although treatment for acute scleroderma renal crisis may arrest the rapid progression of renal disease ...

The hallmark of Systemic Sclerosis is skin thickening. Systemic Sclerosis sine scleroderma is a variant of Systemic sclerosis which shares visceral, serological and vascular manifestations but lacks ...

Despite the improved survival among patients with the serious form of scleroderma (systemic sclerosis; SSc), diffuse cutaneous SSc (dcSSc), over the last decade, there is a significant morbidity ...

After undergoing tests and seeing specialists, the garden designer was diagnosed with diffuse cutaneous systemic sclerosis, a type of scleroderma, a rare autoimmune condition which causes the skin ...

Explore new findings on frailty in systemic sclerosis, revealing its prevalence, dynamic progression, and impact on patient ...

The mildest forms of localised scleroderma may improve on their own over time, while systemic sclerosis can affect blood circulation and the internal organs as well, sometimes leading to life ...

Scleroderma is a chronic autoimmune disease of women. Over time, people living with scleroderma develop progressive and ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase III drugs for Systemic Sclerosis (Scleroderma) ...

Brentuximab vedotin is under clinical development by Pfizer and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) ...